Claims for Patent: 7,939,086

Summary for Patent: 7,939,086

Title:	Modified Vaccinia Ankara virus variant
Abstract:	The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
Inventor(s):	Chaplin; Paul (Munich, DE), Howley; Paul (Berwick, AU), Meisinger-Henschel; Christine (Neuried, DE)
Assignee:	Bavarian Nordic A/S (Kvistgaard, DK)
Application Number:	12/471,144
Patent Claims:	1. A method for inducing a specific immune response in a living animal body comprising administering an isolated MVA-BN virus or a derivative thereof to the animal; wherein the MVA-BN virus or a derivative thereof is characterized by having the capability of reproductive replication in vitro in chicken embryo fibroblasts (CEF) and by being more attenuated than MVA-575 and MVA-572 in the human keratinocyte cell line HaCaT, in the human bone osteosarcoma cell line 143B, in the human cervix adenocarcinoma cell line HeLa, and in the human embryo kidney cell line 293; and wherein a specific immune response is generated in the animal against the MVA-BN virus or a derivative thereof. 2. The method of claim 1, wherein the isolated MVA-BN virus or a derivative thereof is capable of a replication amplification ratio of greater than 500 in CEF cells. 3. The method of claim 1, wherein the animal is a human. 4. The method of claim 2, wherein the animal is a human. 5. The method of claim 1, wherein the isolated MVA-BN virus or a derivative thereof comprises a heterologous nucleic acid sequence. 6. The method of claim 2, wherein the isolated MVA-BN virus or a derivative thereof comprises a heterologous nucleic acid sequence. 7. The method of claim 3, wherein the isolated MVA-BN virus or a derivative thereof comprises a heterologous nucleic acid sequence. 8. The method of claim 4, wherein the isolated MVA-BN virus or a derivative thereof comprises a heterologous nucleic acid sequence. 9. The method of claim 5, wherein the heterologous nucleic acid sequence is selected from a sequence encoding at least one antigen, antigenic epitope, or therapeutic compound. 10. The method of claim 6, wherein the heterologous nucleic acid sequence is selected from a sequence encoding at least one antigen, antigenic epitope, or therapeutic compound. 11. The method of claim 7, wherein the heterologous nucleic acid sequence is selected from a sequence encoding at least one antigen, antigenic epitope, or therapeutic compound. 12. The method of claim 8, wherein the heterologous nucleic acid sequence is selected from a sequence encoding at least one antigen, antigenic epitope, or therapeutic compound. 13. The method of claim 9, wherein the antigen or antigenic epitope is selected from a virus selected from an Influenza virus, a Flavivirus, a Paramyxovirus, a Hepatitis virus, a Cytomegalovirus, a Respiratory Syncitial Virus (RSV), a Measles Virus, a Human immunodeficiency virus, or from a virus causing hemorrhagic fever. 14. The method of claim 10, wherein the antigen or antigenic epitope is selected from a virus selected from an Influenza virus, a Flavivirus, a Paramyxovirus, a Hepatitis virus, a Cytomegalovirus, a Respiratory Syncitial Virus (RSV), a Measles Virus, a Human immunodeficiency virus, or from a virus causing hemorrhagic fever. 15. The method of claim 11, wherein the antigen or antigenic epitope is selected from a virus selected from an Influenza virus, a Flavivirus, a Paramyxovirus, a Hepatitis virus, a Cytomegalovirus, a Respiratory Syncitial Virus (RSV), a Measles Virus, a Human immunodeficiency virus, or from a virus causing hemorrhagic feverr. 16. The method of claim 12, wherein the antigen or antigenic epitope is selected from a virus selected from an Influenza virus, a Flavivirus, a Paramyxovirus, a Hepatitis virus, a Cytomegalovirus, a Respiratory Syncitial Virus (RSV), a Measles Virus, a Human immunodeficiency virus, or from a virus causing hemorrhagic fever. 17. The method of claim 9, wherein the antigen or antigenic epitope comprises a 5T4 tumor antigen. 18. The method of claim 10, wherein the antigen or antigenic epitope comprises a 5T4 tumor antigen. 19. The method of claim 11, wherein the antigen or antigenic epitope comprises a 5T4 tumor antigen. 20. The method of claim 12, wherein the antigen or antigenic epitope comprises a 5T4 tumor antigen. 21. The method of claim 9, wherein the antigen or antigenic epitope comprises a Her-2 tumor antigen. 22. The method of claim 10, wherein the antigen or antigenic epitope comprises a Her-2 tumor antigen. 23. The method of claim 11, wherein the antigen or antigenic epitope comprises a Her-2 tumor antigen. 24. The method of claim 12, wherein the antigen or antigenic epitope comprises a Her-2 tumor antigen. 25. The method of claim 9, wherein the antigen or antigenic epitope is a Bacillus anthracis antigen or antigenic epitope. 26. The method of claim 10, wherein the antigen or antigenic epitope is a Bacillus anthracis antigen or antigenic epitope. 27. The method of claim 11, wherein the antigen or antigenic epitope is a Bacillus anthracis antigen or antigenic epitope. 28. The method of claim 12, wherein the antigen or antigenic epitope is a Bacillus anthracis antigen or antigenic epitope. 29. The method of claim 1, wherein the method comprises administering a priming inoculation and administering a boosting inoculation. 30. The method of claim 2, wherein the method comprises administering a priming inoculation and administering a boosting inoculation. 31. The method of claim 3, wherein the method comprises administering a priming inoculation and administering a boosting inoculation. 32. The method of claim 4, wherein the method comprises administering a priming inoculation and administering a boosting inoculation. 33. The method of claim 1, wherein the MVA-BN is deposited at the European Collection of Cell Cultures (ECACC), Salisbury (UK) under number V00083008.

Details for Patent 7,939,086

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2020-11-23